Advertisement

Topics

Chiesi's limbal stem cell deficiency drug gets FDA orphan status

06:27 EDT 13 Jun 2018 | SmartBrief

Limbal stem cell deficiency drug candidate GPLSCD01 from Chiesi USA received orphan drug status from the FDA. -More

Original Article: Chiesi's limbal stem cell deficiency drug gets FDA orphan status

NEXT ARTICLE

More From BioPortfolio on "Chiesi's limbal stem cell deficiency drug gets FDA orphan status"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...